Viva Biotech Co. Ltd. has agreed to acquire SYNthesis med chem Limited, at the consideration of approximately $80 million. The acquisition will achieve synergies between Viva Biotech and SYNthesis regarding to the CRO business in the global market, which is of great strategic significance for Viva Biotech to conduct vertical integration and establish a comprehensive one-stop drug services platform.   About the Companies   SYNthesis is a preclinical small molecule drug discovery service contract ...